Vanda Reports Wider-than-Expected Loss - Analyst Blog

By
A A A

Vanda Pharmaceuticals Inc. ( VNDA ) reported fourth quarter 2013 net loss per share of 23 cents, flat year over year. The reported loss was wider than the Zacks Consensus Estimate of a loss of 18 cents.

Fourth quarter revenues of $8.8 million were above the year-ago revenues of $7.9 million. Revenues surpassed the Zacks Consensus Estimate of $8 million. Revenues included Fanapt royalties from Novartis ( NVS ) worth $2 million in the reported quarter, above year-ago royalties of $1.2 million. 

According to IMS, Fanapt prescriptions for the fourth quarter were roughly 43,400, up 14% year over year but down 1% sequentially.  

Research and development expenses were $6.2 million, down 41.4% from the year-ago quarter. The decrease was attributable to the completion of efficacy studies for Hetlioz in the treatment of Non-24-Hour sleep-wake disorder (Non-24) and major depressive disorder. We note that the U.S. Food and Drug Administration (FDA) approved Hetlioz 20mg in Jan 2014 for the treatment of Non-24. Hetlioz, the first and only FDA approved medication for Non-24, will be launched in the second quarter of 2014. Vanda expects to file a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for Hetlioz (Non-24) in 2014. 

General and administrative expenses increased to $9.9 million from $3.2 million in the year-ago quarter mainly due to rising commercial activities for the U.S. launch of Hetlioz.

An interesting candidate in Vanda's pipeline is VLY-686. Vanda has initiated a proof of concept study for VLY-686 in the treatment resistant pruritus in atopic dermatitis.

2013 Results

Vanda reported a full year 2013 loss of 67 cents per share, wider than the Zacks Consensus Estimate of a loss of 63 cents but narrower than the 2012 loss of 98 cents per share.

Full year revenues were $33.9 million, almost at par with the Zacks Consensus Estimate of $34 million. Revenues in 2012 were $32.7 million. Revenues included Fanapt royalties from Novartis worth $7.1 million in 2013, above year-ago royalties of $5.9 million. 

Our Take

Vanda carries a Zacks Rank #3 (Hold). The year 2014 will be eventful for Vanda as it launches Hetlioz in the U.S. Investors looking for better-ranked stocks in the biopharma sector may consider companies like Endocyte Inc ( ECYT ) and Biogen Idec Inc. ( BIIB ). Both companies carry a Zacks Rank #1 (Strong Buy).



BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

VANDA PHARMACT (VNDA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: MAA , BIIB , ECYT , NVS , VNDA

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

74,282,785
  • $10.84 ▲ 11.64%
60,794,128
  • $17.12 ▲ 0.71%
55,628,662
  • $35.59 ▼ 1.00%
55,306,290
  • $116.47 ▲ 0.14%
55,118,241
  • $39.75 ▼ 0.43%
53,597,648
  • $9.41 ▲ 8.29%
41,889,990
  • $47.98 ▼ 1.48%
35,692,375
  • $97.34 ▼ 0.57%
As of 11/21/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com